Posted by Michael Wonder on 04 Nov 2025
Benitec Biopharma receives FDA fast track designation for BB-301
3 November 2025 - Benitec Biopharma today provides positive interim clinical results for the BB-301 Phase 1b/2a clinical trial.
Following review of these encouraging interim data, the US FDA has granted fast track designation to BB-301 for the treatment of OPMD with dysphagia.
